Introduction {#Sec1}
============

Angiodysplasias account for up to 5% of all causes of gastrointestinal bleeding and are probably responsible for 60% of cases of small bowel bleeding \[[@CR1]\]. They are a common cause of gastrointestinal bleeding in the elderly \[[@CR2]\]. Presentation includes all aspects of iron-deficiency anemia and gastrointestinal bleeding. The clinical spectrum may range from the absence of symptoms to the refractory anemia with transfusion dependency and frequent hospitalizations.

Angiodysplasias are thought to arise from chronic low-grade intermittent obstruction of submucosal veins leading to capillary congestion and failure of the pre-capillary sphincters \[[@CR3]\]. This results in dilated veins which are prone to bleeding (Fig. [1](#Fig1){ref-type="fig"}). Angiogenic factors \[[@CR4]\] such as vascular endothelial growth factor and Angiopoietin-2 and -1 may play a role \[[@CR5]\]. Thalidomide and somatostatin analogs inhibit angiogenesis and may serve as treatment for gastrointestinal angiodysplasias \[[@CR6]\].Fig. 1Angiodysplasia in the colon. Legend: the differential diagnosis of angiodysplasias consists of other vascular malformations. They are caused by different mechanisms than angiodysplasias, leading to different treatment strategies. Portal hypertensive gastropathy can only develop in the presence of increased portal pressure. Histological (submucosal) biopsies show dilation and congested, tortuous submucosal venules \[[@CR7]\]. This also differentiates from gastric antral vascular ectasias where biopsies show the presence of fibrin thrombi in dilated capillaries and fibromuscular proliferation in the lamina propria. As the name suggests, these two vascular diseases are limited to stomach involvement. Radiation-induced telangiectasias are caused by the toxicity of radiotherapy. The found telangiectasias are often multiple, and involvement is delimited to the area that received radiation \[[@CR8]\]. Eosinophilic infiltrates, epithelial atypia, fibrosis and capillary telangectasia can be found in histological specimens. As last, a dieulafoy lesion is a submucosal artery that erodes the overlying epithelium and is of prominent caliber due to abnormal branching without the presence of an ulcer. These lesions might not be seen during endoscopy in case they are not actively bleeding \[[@CR9]\]. The congenital inherited diseases hereditary hemorrhagic teleangectasia, blue rubber bleb nevus syndrome and Klippel--Trénaunay syndrome can present with angiodysplastic features during endoscopy; however, these disorders often become symptomatic at a young age, and the vascular malformations are present in multiple organs \[[@CR10]\]

In addition to an increasing age, there are a number of predisposing conditions such as Von Willebrand disease, aortic stenosis (Heyde's syndrome) and chronic kidney disease \[[@CR11]--[@CR14]\]. The introduction of the colorectal cancer screening program has led to a major increase in number of endoscopies performed in the population older than 55 years with a positive immunological fecal occult blood test \[[@CR15]\]. This will probably contribute to a further increase in diagnosis of (asymptomatic) angiodysplasias. Collectively, this has led to the increase in angiodysplasia related hospitalizations from 0.9 (1996) to 2.6 (2005) per 100.000 person-years \[[@CR16]\].

Little is known about the nature of risk factors that contribute to the development of angiodysplasias. Better understanding of these factors may help to predict which patient is at risk to develop symptoms from angiodysplasias. High risk may warrant preemptive therapeutic argon plasma coagulation at time of diagnosis, close follow-up and/or initiation of angiogenesis inhibitors in an earlier stage. Secondly, elimination of those triggers that cause bleeding may serve as a preferential strategy in patients with recurrent angiodysplasia bleeding or chronic transfusion dependency. Finally, there is a wide variety of disease burden in patients with angiodysplasias \[[@CR17]\]. The consequence is that most angiodysplasia studies are heterogeneous by nature and that extrapolation of results is difficult \[[@CR18]--[@CR23]\]. We used a systematic review in order to provide a comprehensive overview of risk factors associated with different disease stages: angiodysplasias found during endoscopy, angiodysplasias that lead to anemia or overt bleeding and factors of influence on recurrent bleeding and mortality.

Methods {#Sec2}
=======

This study is in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR24]\].

Literature Search {#Sec3}
-----------------

A systematic search was conducted with the aid of an expert librarian. We retrieved relevant publications from MEDLINE and Cochrane Library up to August 2018 and for the EMBASE database up to August 2016. We used search terms for the determinant 'gastrointestinal angiodysplasia' with synonyms for the outcome 'risk factor' (see supplementary file, search strategy). Titles, abstracts and subsequent full-text articles were independently screened by two authors (K.V.G. and M.M.) based on predefined selection criteria. Disagreement on eligibility was resolved through consensus. The search was completed by hand-searching the references of the selected articles, related reviews, meta-analyses and guidelines.

Inclusion and Exclusion Criteria {#Sec4}
--------------------------------

We selected published articles that reported on studies assessing risk factors for angiodysplasias detected during endoscopy or that investigated factors that contribute to symptomatic angiodysplasia bleeding, or more severe disease including rebleeds or mortality due to gastrointestinal angiodysplasias bleeding. Symptomatic disease is defined as angiodysplasias that cause anemia or overt bleeding. We excluded the following type of studies: case reports, case series \< 40 patients, reviews, editorials, opinion papers, animal or children studies, nonclinical studies. The search was not time limited. Non-Dutch and non-English language articles were excluded. Finally, studies that included vascular malformations other than angiodysplasias of the GI system, such as portal hypertensive gastropathy, radiation telangiectasia, hereditary hemorrhagic telangiectasia and gastric antral vascular ectasia, were excluded. The diagnosis of angiodysplasia had to be made through endoscopy, which also includes wireless video capsule endoscopy, or identification by International Statistical Classification of Diseases (ICD)-codes (ICD-9 537.82, 537.83, 569.84 and ICD-10 K55.20, K55.21).

Data Extraction {#Sec5}
---------------

The following study characteristics were extracted from each study in a standardized manner: year of publication, country of origin, study design and population, sample size and type of control group. The preferred outcomes were odd's ratios (OR) or hazard ratios (HR) with their 95% confidence intervals (95%-CI). If not available the reported outcomes such as prevalence were drawn from the original manuscript.

Quality Assessment {#Sec6}
------------------

Eligible articles were critically appraised for relevance and internal validity. The quality of each study was assessed with the Newcastle--Ottawa Quality Assessment Scale for nonrandomized studies \[[@CR25]\]. The following domains of bias were addressed: representativeness of the cases, adequate selection, comparability, outcome assessment and follow-up. Each of the eight items can be scored as adequate using an X, except for the domain comparability which is given two Xs. The overall rating of the risk of bias is scored as low (7--9 X), moderate (4--6 X) or high (0--3 X). Publication bias was assessed graphically with a funnel plot.

Statistical Analysis and Risk Assessment {#Sec7}
----------------------------------------

Due to variations in study population, methodologies and measurements between studies, a formal meta-analysis was deemed inappropriate here. A 95% confidence interval (95% CI) not including 0 or a two-sided tested *p* value ≤ 0.05 was considered statistically significant.

The risk assessment identifies important risk factors based on two criteria: strength of evidence and effect size. When risk factors were identified by at least two independent studies, those factors were identified as more important due to the increased strength in evidence \[[@CR26]\] A risk factor identified by one study with a moderate (OR 3.5--6.6) or large effect size (OR ≥ 6.7) was ought to be important as well based on it is effect size \[[@CR27]\].

Results {#Sec8}
=======

The original search yields 1322 citations, after applying the in- and exclusion criteria for study selection, and 23 studies were included for qualitative synthesis (see Fig. [2](#Fig2){ref-type="fig"}: flow diagram). Most studies were excluded because they did not match our study aim (e.g., these studies focused on treatment efficacy or diagnostic modalities) or because they were case reports or conference abstracts. Two additional studies that fit inclusion criteria were discovered through checking the references of the included studies. Within the set of 23 reviewed studies included in our systematic review, 13 (*n* = 1429 patients) were on risk factors associated with the presence of angiodysplasia during endoscopy, two dealt with triggers for symptomatic angiodysplasias (*n* = 4594 patient) and eight assessed risk factors for rebleeds and mortality (*n* = 86,611 patients).Fig. 2Flow diagram of the search results

Study Assessment {#Sec9}
----------------

Risk of bias was introduced at different levels and was mostly dependent on the design of the study (supplementary file, Table 1). Funnel plot showed similar estimates (OR) with similar sample sizes, which lead to asymmetry and could be an indication for a risk of publication bias (supplementary file, figure 2). No statistical tests were performed to detect bias, because of the large between-study heterogeneity. Overall, the risk of bias was judged as high in six studies, moderate in 17 studies and low in one study. The quality of evidence was too low to perform a meta-analysis.

Risk Factors for Angiodysplasias Found During Endoscopy {#Sec10}
-------------------------------------------------------

Thirteen studies assessed risk factors for the presence of angiodysplasias detected during endoscopy (Table [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}) \[[@CR15], [@CR28]--[@CR39], [@CR41]\]. Nine studies (Table [1](#Tab1){ref-type="table"}) assessed risk factors for the presence of angiodysplasias in patients with overt or occult gastrointestinal bleeding compared to patients without angiodysplasias and bleeding. Independent risk factors that were confirmed in two or more studies were increasing age (OR 1.09 per year, 95% CI 1.04--1.1), chronic kidney disease (OR 4.5, 95% CI 1.9--10.5) and cardiovascular disease (OR 2.9, 95% CI 1.4--6.2). The association between liver cirrhosis and the presence of angiodysplasias in overt or occult bleeding patients had a moderate effect size (OR 4.8, 95% CI 1.8--14.5). Table 1Studies assessing factors associated with the presence of gastrointestinal angiodysplasias (GIAD) compared to no angiodysplasias in patients with overt or occult bleedingAuthor Country, yearStudy typeNo. of comparison patientsNo. of GIAD ptsEndoscopy method and indicationStudy populationOutcomesSignificant risk factorsEffectOR (95%-CI)/*t* testIgawa et al. Japan, 2015 \[[@CR28]\]CC9764SBCE and balloon endoscopy for OGIBSmall bowel GIADLiver cirrhosis4.8 (1.8--14.5)Cardiovascular disease2.9 (1.4--6.2)Macdonald et al. UK, 2010 \[[@CR30]\]CC9146SBCE, 72% OGIBGIADIncreasing age1.09 (1.04--1.1)Chak et al. USA, 1998 \[[@CR31]\]CC9732Push enteroscopy for: 40% OGIB, 39% overt bleeding, 12% diarrhea, 9% mucosal diseaseGIADAge 40% \> 65 years versus 12% \< 65 years*P* \< 0.001CKD 54% in GIAD versus 27% control*P* \< 0.05, OR 3.2Clouse et al. USA, 1985 \[[@CR32]\]CC9030EGD for suspected upper GI bleedingGIADCKD 60% in GIAD versus 24% control*P* \< 0.001 OR 4.6Blackshear et al. USA, 2014 \[[@CR34]\]RC467Endoscopy NSMitral valve regurgitation and GIAD13.2% GIAD in pts with mitral valve regurgitationNAFrench et al. USA, 2013 \[[@CR35]\]RC31--EGD, colonoscopy or push enteroscopy for bleeding eventLVAD and GIADGIAD as cause in 17.5% of all GI bleeding events in LVADNABhutani et al. USA, 1995 \[[@CR38]\]PC3740EGD or colonoscopy for: polyps/cancer 18%, anemia 30%, overt bleeding 35%, dyspepsia 18%GIAD pts0% aortic stenosisNAMarcuard et al. USA, 1988 \[[@CR39]\]Cohort3215Overt GI bleeding, AGD or colonoscopyGIAD in dialysis pts32% of CKD pts with GI bleeding have GIADNASotoudehmanesh et al. Iran, 2003 \[[@CR36]\]PC1979Routine EGD before renal transplantGIAD in dialysis pts ± GI bleedingIncidence in pre-renal transplant pts: 4.4% GIADNATable 2Studies assessing risk factors for bleeding angiodysplasias compared to patients without gastrointestinal bleedingAuthor Country, yearStudy typeNo. of pts controlsNo. of pts with GIADStudy populationComparison groupOutcomeEffect HR (95%-CI)/*t* testHolleran et al. Ireland, 2013 \[[@CR29]\]CC9566Small bowel GIAD at SBCE/51% anemia, 23% overt bleeding, 15% OGIB, 11% otherNo GI bleeding/determined by two negative FOBT for colorectal cancer screening programHypertension2.8 (1.5--5.4)Ischemic heart disease4.3 (1.9--9.8)Arrhythmias4.4 (1.7--11.2)Valvular heart disease18.8 (2.4--149.6)Congestive cardiac failure4.5 (1.2--17.9)CKD4.5 (1.9--10.5)Previous VTE6.4 (1.3--31.3)Anticoagulant use^a^2.7 (1.4--5.1)Warfarin^a^5.5 (1.1--27.5)Proton pump inhibitor^a^5.4 (2.7--10.7)Cochrane et al. USA, 2016 \[[@CR33]\]CC5614LVAD and GIAD diagnosed with EGD or colonoscopyLVAD without GI bleedingAge1.3 (1.1--1.6)CKD21.0 (2.5--181)Length of stay after LVAD5.1 (1.1--23.7)Sex: male0.1 (0.01--0.9)Diabetes mellitus0.9 (0.01--0.6)Hypertension0.2 (0.1--0.97)Duchini et al. USA, 1998 \[[@CR37]\]RC1359SS/CREST and GIAD bleeding/endoscopy or radiology NSSS/CREST without clinical signs of GI bleeding6.3% have GI bleeding due to GIADNAKim et al. Korea, 2016 \[[@CR41]\]RC3558UGIB due to GIAD, diagnosed with EGD, SBCE or colonoscopyAsymptomatic health screeningSize AD ≥ 1 cm-- (1.04--15.9)Site: stomach-- (1.2--12.5)*CC* case--control study, *RC* retrospective cohort, *PC* prospective cohort, *GIAD* gastrointestinal angiodysplasias, *OGIB* occult gastrointestinal bleeding, *OR* Odds ratio, *VTE* venous thromboembolism, *LVAD's* left ventricular assist devices, *GI* gastrointestinal, *CKD* chronic kidney disease, *NSAID* nonsteroidal anti-inflammatory drugs, *PPI* proton pump inhibitor, *yrs* years, *FOBT* fecal occult blood test, *pts* patients, *SBCE* small bowel capsule endoscopy, *EGD* esophagogastroduodenoscopy, *NA* not applicable, -- missing^a^Analysis: not reported univariate or multivariate analysis

In Table [2,](#Tab2){ref-type="table"} studies are shown that assess the presence of symptomatic angiodysplasias compared to patients without gastrointestinal bleeding. Chronic kidney disease was associated with two studies with bleeding angiodysplasias (OR 4.5 and 21.0). The association between the following conditions and bleeding angiodysplasias had a moderate to large effect size: valvular heart disease (OR 18.8, 95% CI 2.4--149.6), previous venous thromboembolism (OR 6.4, 95% CI 1.3--31.3), Warfarin use (OR 5.5, 95% CI 1.1--27.5), proton pump inhibitor use (OR 5.4, 95% CI 2.7--10.7), congestive heart failure (OR 4.5, 95% CI 1.2--17.9), arrhythmias (OR 4.4, 95% CI 1.7--11.2) and ischemic heart disease (OR 4.3, 95% CI 1.9--9.8).

In studies focused one specific patient category, the following conditions are risk factors for angiodysplasias: LVADs, mitral valve regurgitation \[[@CR34]\] and systemic sclerosis and calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly and telangiectasia (CREST) syndrome (6.3% of GI bleeding due to AD) \[[@CR35], [@CR38]\]. Hypertension was identified as a risk factor for small bowel disease (OR 2.8, 95% CI 1.5--5.4) \[[@CR29]\], although its presence may confer protection against bleeding in patients with LVADs (OR 0.2, 95% CI 0.1--0.97) \[[@CR33]\].

Triggers for Angiodysplasia Causing Overt or Occult Bleeding {#Sec11}
------------------------------------------------------------

Only two retrospective cohort studies assessed factors that trigger symptomatic disease defined as anemia or overt GI bleeding (Table [3](#Tab3){ref-type="table"}) \[[@CR40]--[@CR42]\]. Both studies only include colon angiodysplasias. Independent risk factors identified by two studies for symptomatic disease were age above 80 years (OR 5.2 and 1.3) and multiple lesions (OR 6.7 and 2.2). The study by Diggs et al. \[[@CR42]\] is a population-based study with a large sample size (*n* = 4159). Inpatient status had the largest effect size in this study with an OR of 8.7 (95% CI 5.4-14.1). Nishiruma et al. \[[@CR40]\] found heart disease in past medical history (OR 6.9, 95% CI 1.0--45.5) and angiodysplasia lesions ≤ 5 mm (OR 17.7, 95% CI 4.9--64.0) as risk factors with a large effect size.Table 3Studies assessing triggers for overt or occult bleeding in patients with angiodysplasiasAuthor Country, yearStudy typeNo. of pts symptomaticNo. of pts asymptomaticInclusion type of GIADComparison groupOutcomesSignificant risk factors multivariate analysisEffect OR (95%-CI)Nishimura et al. Japan, 2016 \[[@CR40]\]RC29406Colon, active bleeding during endoscopyNo active bleeding GIAD during colonoscopyAge \> 80 years5.15 (1.61--16.5)Heart disease6.88 (1.04--45.5)Anticoagulant use4.22 (1.21--14.7)Multiple lesions6.67 (1.77--25.2)AD lesions ≤ 5 mm17.7 (4.90--64.0)Diggs et al. USA, 2011 \[[@CR42]\]RC23201839Colon angiodysplasia with occult or overt bleedingColon angiodysplasia without occult or overt bleedingInpatient status8.74 (5.4--14.1)Age \> 80 years1.32 (1.1--1.6)ASA class ≥ III1.97 (1.6--2.4)Black race1.95 (1.5--26.6)Hispanic ethnicity1.71 (1.3--2.2)2--10 lesions1.50 (1.3--1.8)\> 10 lesions2.18 (1.7--2.8)*PC* prospective cohort, *RC* retrospective cohort, *GI* gastrointestinal, *No* number, *GIAD* angiodysplasia, *pts* patients, *UGIB* upper GI bleeding, *OR* odds ratio, *CI* confidence interval, *ASA* American Society of Anesthesiologists, -- missing

Predictors for Rebleeding and Mortality in Patients with Symptomatic Angiodysplasias {#Sec12}
------------------------------------------------------------------------------------

Six retrospective cohort studies investigated factors associated with rebleeds in a population of symptomatic patients (Table [4](#Tab4){ref-type="table"}) \[[@CR12], [@CR43]--[@CR49]\]. Two studies assessed risk factors for mortality \[[@CR43], [@CR49]\]. One scrutinized the natural history of GI bleeding in VWD \[[@CR12]\]. Independent risk factors for rebleeding identified by at least two studies are multiple lesions (OR 4.2, 95% CI 1.1--16.2 and 3.8, 95% CI 1.3--11.3 and 8.6, 95% CI 1.4--52.6) \[[@CR46]--[@CR48]\]. In addition, liver cirrhosis (OR 4.0), location in the third small bowel quartile (OR 4.3), chronic kidney disease (4.5), congestive heart failure (4.5) and a prothrombin time \< 30% (OR 4.2) were detected as bonafide risk factors with a moderate effect size. Prothrombin time was studied in the setting of acute GI bleeding \[[@CR48]\]. Multiple (≥ 3) comorbidities led to an increased risk (OR 2.3, 95% CI 1.2--4.3) of in-hospital mortality and inpatient status to an increased 90-day mortality (OR 17.7, 95% CI 1.7--185.1) in patients with angiodysplasias \[[@CR49]\].Table 4Patient characteristics predicting rebleeds and mortality in patients with symptomatic angiodysplasiasAuthor Country, yearStudy typeNo. of AD pts analyzedNo. of pts with rebleedsType/detection of ADFollow-up: % and yearsOutcomeOutcomesSignificant risk factors multivariate analysisEffect OR/HR (95%-CI)Mai et al. USA, 2017 \[[@CR43]\]RC8714SBA, capsule endoscopy100% at least 1 yearRebleedsNon-isolated GIAD4.2 (1.1--16.2)Chronic kidney disease4.5 (1.0--19.6)Congestive heart failure4.5 (1.0--19.9)90-day mortalityInpatients17.7 (1.7--185.1)Kaufman et al. USA, 2016 \[[@CR44]\]RC15646SBA, capsule endoscopy--RebleedsAge of diagnosis1.05 (1.01--1.09)Active bleeding on capsule endoscopy2.69 (1.15--6.30)Location: quartile 34.29 (1.46--12.56)Jeon et al. Korea, 2016 \[[@CR45]\]RC6615Balloon assisted enteroscopy90%, mean 1.8RebleedsLiver cirrhosis4.01 (1.1--15.0)Holleran et al. Ireland, 2016 \[[@CR46]\]RC5645SBA, capsule endoscopy65%, mean 2.7RebleedsMultiple lesions--Valvular heart disease--Sakai et al. Japan, 2014 \[[@CR47]\]RC6823Capsule endoscopy92%, median 2.5Rebleeds≥ 3 angiodysplasias3.82 (1.3--11.3)Saperas et al. Spain, 2009 \[[@CR48]\]RC5717Acute GI bleeding due to GIAD, endoscopy NS92%, mean 2.8RebleedsOver-anticoagulation4.15 (1.1--15.4)Multiple lesions8.63 (1.4--52.6)Makris et al. UK, 2015 \[[@CR12]\]RC48--Congenital VWD with GI bleeding, diagnosed by all types of endoscopy/angiography/imaging scans--37.5% AD cause of GI bleedingNANASerrao et al. USA, 2016 \[[@CR49]\]RC85971--GIAD by EGD, ICD-codes100%, one hospital admissionIn-hospital mortality≥ 3 comorbidities2.29 (1.2--4.3)*PC* prospective cohort, *RC* retrospective cohort, *OR* odds ratio, *HR* hazard ratio, *CI* confidence interval, *SBA* small bowel angiodysplasias, *GIAD* gastrointestinal angiodysplasias, *ICD* international classification of diseases, *NA* not applicable, *endoscopy NS* type of endoscopy not specified, -- missing

Discussion {#Sec13}
==========

This systematic review gives an overview of risk factors associated with detection of angiodysplasias during endoscopy, triggers for overt or occult bleeding and factors that contribute to rebleeds and mortality as a result of angiodysplasias. Age, chronic kidney disease, anticoagulant use and cardiovascular disease are the most important factors associated with the detection of angiodysplasias during endoscopy \[[@CR16], [@CR28], [@CR29]\]. In view of the pathophysiological hypothesis, it is plausible that age, chronic kidney and cardiovascular disease contribute to development of angiodysplasias. Inpatient status is strongly associated with bleeding disease; however, this association with inpatient status is probably the consequence of the bleeding rather than an etiologic factor and thereby not clinically significant. Multiple lesions increase the risk of rebleeds.

The over-arching aim of this systematic review is to define factors that determine the presence of gastrointestinal angiodysplasias and/or affect the progression to symptomatic disease. The use of a risk stratification to guide management requires a thorough assessment of the contribution of individual risk factors to the clinical picture. Patients who develop bleeding angiodysplasias and possess multiple risk factors that amplify the risk for rebleeding deserve close monitoring but also reassessment of those conditions that put the patient at a higher risk. For example, (over-) anticoagulation and valvular heart disease can be amended or treated. The efforts needed to lower the risk profile by treating underlying conditions can be complimentary to aggressive endoscopic treatment. Efforts to investigate the efficacy of different treatment strategies in low and high risk patients in order to fuel the evidence base are welcome.

At present, one of the major issues in clinical management of asymptomatic angiodysplasias is that evidence on treatment outcome is based on heterogeneous small and often non-controlled studies \[[@CR18]--[@CR22], [@CR50]--[@CR54]\]. This results in considerable practice variation \[[@CR55]\]. More understanding of the different risk profiles of patients with different severity of the disease helps to make the right decision in whether to treat and which treatment modality would be needed.

This systematic review allows identification of gaps that helps in the management of this disease. It also illustrates the complexity and wide phenotypical range of disease severity. In comparison with other vascular malformations, such as GAVE, portal gastropathy and radiation-induced telangiectasias, the most prominent risk factors for the development of angiodysplasias and severity of the disease remain to be further investigated.

Our systematic review comes with inherent strengths and limitations. The strength of this study is that it includes a broad search strategy with a thoroughly performed quality assessment. Moreover, risk assessment based on confirmation of risk factors in a second study and those with a moderate effect size (OR \> 3.5) is performed. To get a clear overview, we subdivided the risk factors for different stages of disease, i.e., risk to detect angiodysplasias during endoscopy, angiodysplasias that cause overt bleeding or anemia and a more severe course with rebleeds or mortality. In addition, the risk factors for each different disease stage include Western and Asian studies, thereby increasing the external validity of this review. A limitation of the study is that a meta-analysis was not possible due to the methodological heterogeneity between the studies. Moreover, the majority of studies identifying risk factors for finding angiodysplasias during endoscopy use different control groups and indications for endoscopy or only focus on small bowel angiodysplasias. We excluded case reports and small case series which could have led to the exclusion of diseases which are rare that increase the risk of the presence of angiodyplasias, e.g., bone marrow transplantation. We excluded other vascular anomalies, which could have introduced bias due to the inaccuracy of correctly distinguishing angiodysplasias from other vascular lesions at video capsule endoscopy.

In conclusion, this systematic review identified important risk factors for angiodysplasias at different disease stages. The risk assessment identified age, chronic kidney disease and cardiovascular disease as the most important risk factors for the presence of angiodysplasias during endoscopy and multiple lesions contributing to disease severity. Information on these risk factors aids in accurate phenotyping which benefits clinical decision making.
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